er-stress-neurodegeneration

Endoplasmic Reticulum Stress in Neurodegeneration

Introduction

Endoplasmic Reticulum Stress In Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

Endoplasmic reticulum (ER) stress is a central pathological mechanism in [neurodegenerative diseases, triggered when the [@hetz2015]
accumulation of unfolded or misfolded proteins in the ER lumen exceeds the organelle's folding capacity. The ER is the primary site for [@xu2022]
synthesis, folding, and post-translational modification of secretory and transmembrane proteins, and its dysfunction activates a complex [@ref2017]
adaptive signaling network known as the [unfolded protein response](/entities/unfolded-protein-response) (UPR). While the [endoplasmic-reticulum-stress](/mechanisms/endoplasmic-reticulum-stress) initially functions as a protective mechanism to [@bruch2019]
restore proteostasis, chronic or excessive ER stress shifts the response from adaptive to maladaptive, ultimately triggering apoptotic [@chen2026]
cell death pathways that are particularly devastating in post-mitotic [neurons](/entities/neurons) with limited regenerative capacity [@zhang2023]
[@ref] [@khan2023]
[@hetz2015]. [@liao2025]

...

Endoplasmic Reticulum Stress in Neurodegeneration

Introduction

Endoplasmic Reticulum Stress In Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

Endoplasmic reticulum (ER) stress is a central pathological mechanism in [neurodegenerative diseases, triggered when the [@hetz2015]
accumulation of unfolded or misfolded proteins in the ER lumen exceeds the organelle's folding capacity. The ER is the primary site for [@xu2022]
synthesis, folding, and post-translational modification of secretory and transmembrane proteins, and its dysfunction activates a complex [@ref2017]
adaptive signaling network known as the [unfolded protein response](/entities/unfolded-protein-response) (UPR). While the [endoplasmic-reticulum-stress](/mechanisms/endoplasmic-reticulum-stress) initially functions as a protective mechanism to [@bruch2019]
restore proteostasis, chronic or excessive ER stress shifts the response from adaptive to maladaptive, ultimately triggering apoptotic [@chen2026]
cell death pathways that are particularly devastating in post-mitotic [neurons](/entities/neurons) with limited regenerative capacity [@zhang2023]
[@ref] [@khan2023]
[@hetz2015]. [@liao2025]

The neurodegenerative diseases most prominently linked to ER stress include [alzheimers](/diseases/alzheimers-disease), [parkinsons](/diseases/parkinsons-disease), [als](/diseases/als), [huntington-pathway](/mechanisms/huntington-pathway), [prion-disease](/diseases/prion-disease), and [ftd](/diseases/ftd). Each of these disorders is [@hughes2019]
characterized by the accumulation of specific misfolded proteins—[amyloid-beta](/proteins/amyloid-beta) and tau] in AD, [alpha-synuclein](/proteins/alpha-synuclein) [@gallardo2025]
in PD, [sod1-protein](/proteins/sod1-protein)/[tdp-43](/proteins/tdp-43)/[fus](/entities/fus) in ALS, [huntingtin](/proteins/huntingtin) in HD—that directly or indirectly overwhelm [@hetz2017]
ER protein quality control systems [@ref] [@xu2022].

\n## The Unfolded Protein Response: Three Signaling Arms

The endoplasmic-reticulum-stress is coordinated by three ER-resident transmembrane sensor proteins: PERK (PKR-like endoplasmic reticulum kinase), IRE1alpha
("inositol-requiring enzyme 1alpha"), and ATF6 (activating transcription factor 6). Under normal conditions, all three sensors are maintained in

an inactive state through binding of the ER chaperone BiP/GRP78 to their luminal domains. When unfolded proteins accumulate, BiP dissociates
from the sensors to assist in protein folding, thereby activating each pathway
[@hetz2015]
[@ref2017].

PERK–eIF2α–ATF4 Pathway

PERK activation is initiated by BiP dissociation and subsequent oligomerization and trans-autophosphorylation of the PERK kinase domain.
Active PERK phosphorylates eukaryotic initiation factor 2α (eIF2α) at serine 51, which dramatically reduces global cap-dependent mRNA
translation, thereby decreasing the protein load entering the ER. Paradoxically, p-eIF2α selectively enhances translation of specific mRNAs
containing upstream open reading frames (uORFs), most notably ATF4 (activating transcription factor 4). ATF4 is a transcription factor that
upregulates genes involved in amino acid metabolism, redox homeostasis, and [autophagy](/mechanisms/autophagy-lysosome-neurodegeneration)mechanisms/autophagy)
[@hetz2015]
[@bruch2019].

Under prolonged stress, ATF4 induces expression of CHOP (C/EBP homologous protein, also known as DDIT3/GADD153), a transcription factor that
promotes [apoptosis](/mechanisms/apoptosis) by downregulating the anti-apoptotic protein Bcl-2, upregulating pro-apoptotic BH3-only proteins (Bim, PUMA), and
increasing expression of GADD34, which dephosphorylates eIF2α to restore translation—creating a vicious cycle of increased protein load in
an already stressed ER. CHOP also upregulates ER oxidase ERO1α, increasing [oxidative-stress](/mechanisms/oxidative-stress) production within the ER lumen
[@xu2022]
[@bruch2019].

The PERK pathway has been identified as particularly important in neurodegeneration, giving rise to the concept of "PERK-opathies"—diseases driven primarily by dysregulation of the PERK signaling axis. Mutations in PERK itself cause Wolcott-Rallison syndrome, which includes neurological features, while downstream effectors of PERK signaling are implicated across multiple neurodegenerative conditions
[@bruch2019].

IRE1α–XBP1 Pathway

IRE1α is the most evolutionarily conserved [endoplasmic-reticulum-stress](/mechanisms/endoplasmic-reticulum-stress) sensor. Upon activation, IRE1α dimerizes and undergoes trans-autophosphorylation, activating its cytoplasmic endoribonuclease (RNase) domain. The RNase domain performs an unconventional splicing reaction on XBP1 mRNA, removing a 26-nucleotide intron to generate the spliced form XBP1s. XBP1s is a potent transcription factor that upregulates genes encoding ER chaperones (BiP, GRP94, calreticulin), components of ER-associated degradation (ERAD), and phospholipid synthesis enzymes that expand ER membrane capacity
[@ref]
[@ref2017].

Under chronic stress, the IRE1α RNase domain also performs regulated IRE1-dependent decay (RIDD) of mRNAs, including those encoding
ER-targeted proteins. While RIDD initially reduces ER protein load, excessive RIDD can degrade mRNAs encoding essential proteins and
microRNAs that repress pro-apoptotic factors, thereby promoting cell death. Additionally, activated IRE1α recruits TRAF2 (TNF
receptor-associated factor 2), which activates the ASK1–JNK (c-Jun N-terminal kinase) cascade, linking ER stress to inflammatory signaling
through [nf-kb](/entities/nf-kb) and [apoptosis](/mechanisms/apoptosis) through mitochondrial pathways
[@ref]
[@hetz2015].

ATF6 Pathway

ATF6 exists as two isoforms (ATF6α and ATF6β). Under ER stress, ATF6 translocates from the ER to the Golgi apparatus, where it is sequentially cleaved by site-1 protease (S1P) and site-2 protease (S2P)—the same proteases involved in cholesterol metabolism regulation. The cleaved N-terminal cytoplasmic fragment (ATF6f) translocates to the nucleus, where it activates transcription of ER chaperone genes (BiP, GRP94), ERAD components, and XBP1 (amplifying the IRE1α pathway). ATF6α also induces DAPK1 (death-associated protein kinase 1) and CHOP, contributing to pro-apoptotic signaling under sustained stress
[@ref]
[@ref2017].

ER-Associated Degradation (ERAD)

ERAD is a critical protein quality control mechanism that identifies terminally misfolded proteins in the ER, retrotranslocates them to the
cytoplasm through the Sec61 translocon or Derlin channels, and targets them for degradation by the [ubiquitin-proteasome-system](/mechanisms/ubiquitin-proteasome-system). The ERAD
machinery includes recognition lectins (OS-9, XTP3-B), retrotranslocation channel components (Hrd1, SEL1L, Derlin-1/2/3), ubiquitin ligases
(Hrd1, gp78, MARCH6), the p97/VCP AAA-ATPase that provides the mechanical force for extraction, and deglycosylation enzymes (PNGase) [@chen2026].

Dysfunction of ERAD components has been directly linked to neurodegeneration. Mutations in VCP/p97 cause inclusion body myopathy with Paget disease and Frontotemporal Dementia (IBMPFD), and Hrd1 deficiency in mice leads to neuronal loss. Notably, disease-associated misfolded proteins such as expanded polyglutamine repeats and mutant SOD1 can physically clog the ERAD machinery, creating a feedforward loop of ER stress amplification
[@chen2026].

ER Stress in Specific Neurodegenerative Diseases

Alzheimer's Disease

ER stress is deeply intertwined with [alzheimers](/diseases/alzheimers-disease) pathogenesis at multiple levels. Postmortem AD brains show significantly elevated
levels of [endoplasmic-reticulum-stress](/mechanisms/endoplasmic-reticulum-stress) activation markers including p-PERK, p-eIF2α, p-IRE1α, ATF4, and CHOP, with levels correlating with Braak stage
(neurofibrillary tangle burden) and preceding overt neurodegeneration. The [psen1](/genes/psen1) and [psen2](/genes/psen2) mutations that cause familial
AD directly perturb ER calcium homeostasis by functioning as ER calcium leak channels, and mutations reduce this leak function, leading to
ER calcium overload and impaired chaperone activity
[@xu2022]
[@zhang2023].

[amyloid-beta](/proteins/amyloid-beta) oligomers trigger ER stress through multiple mechanisms: direct interaction with ER membranes, disruption of ER calcium stores via [ryanodine-receptor](/entities/ryanodine-receptor) and IP3 receptor sensitization, and impairment of ERAD function. [tau-protein](/proteins/tau) hyperphosphorylation] is both a cause and consequence of ER stress—p-PERK co-localizes with p-tau] in AD [neurons](/entities/neurons), and the PERK–[gsk3-beta](/mechanisms/gsk3-beta) axis directly phosphorylates [tau](/proteins/tau) protein], while aggregated [tau](/proteins/tau) impairs ERAD by interacting with the proteasomal machinery
[@xu2022].

Parkinson's Disease

In [parkinsons](/diseases/parkinsons-disease), α-synuclein oligomers and aggregates trigger ER stress by multiple mechanisms. Wild-type α-synuclein directly
binds to BiP/GRP78 in the ER lumen, and A53T mutant α-synuclein shows enhanced ER localization and greater [endoplasmic-reticulum-stress](/mechanisms/endoplasmic-reticulum-stress) activation. α-Synuclein
oligomers block ER-to-Golgi vesicular transport by binding to Rab1 GTPase, causing accumulation of cargo proteins within the ER.
Dopaminergic [neurons](/entities/neurons) in the [substantia-nigra](/brain-regions/substantia-nigra) are particularly susceptible to ER stress due to the oxidative burden of [dopamine](/entities/dopamine)
metabolism, which generates reactive quinones that modify ER-resident proteins
[@ref]
[@hetz2015].

The [pink1](/proteins/pink1-protein)/[prkn](/genes/prkn) mitochondrial quality control pathway intersects with ER stress through mitochondria-associated ER membranes (MAMs)—physical contact sites where mitochondria and ER exchange calcium, lipids, and signaling molecules. PINK1 and Parkin regulate MAM integrity, and their loss-of-function disrupts ER-mitochondrial calcium transfer, contributing to both ER stress and [mitochondrial-dysfunction](/mechanisms/mitochondrial-dysfunction). [lrrk2](/proteins/lrrk2-protein) mutations, the most common genetic cause of PD, also activate the PERK pathway through mechanisms involving impaired vesicular trafficking [@ref].

Amyotrophic Lateral Sclerosis

Motor [neurons](/entities/neurons) are extraordinarily susceptible to ER stress due to their extreme morphological polarization (axons can be >1 meter long),
high secretory demand, and limited [endoplasmic-reticulum-stress](/mechanisms/endoplasmic-reticulum-stress) capacity. In [als](/diseases/als), mutant [sod1-protein](/proteins/sod1-protein) protein mislocalizes to the ER lumen,
where it interacts with BiP and Derlin-1, directly engaging and overwhelming the [endoplasmic-reticulum-stress](/mechanisms/endoplasmic-reticulum-stress) machinery. [tdp-43](/proteins/tdp-43) pathology, present in ~97% of ALS
cases, disrupts ER function by altering mRNA processing of ERAD components and ER chaperones. [fus](/entities/fus) mutations impair stress granule dynamics
that normally sequester translationally stalled mRNAs during ER stress, creating aberrant persistent stress granules that evolve into
pathological inclusions [@ref]
[@hetz2015].

[c9orf72](/genes/c9orf72) repeat expansions, the most common genetic cause of ALS/FTD, produce dipeptide repeat (DPR) proteins through repeat-associated non-AUG (RAN) translation that accumulate in the ER and activate all three [endoplasmic-reticulum-stress](/mechanisms/endoplasmic-reticulum-stress) arms. The arginine-containing DPRs (poly-GR, poly-PR) are particularly toxic and impair nucleocytoplasmic transport, further disrupting the cellular stress response [@ref].

Huntington's Disease

Mutant [huntingtin](/proteins/huntingtin) protein] with expanded polyglutamine tracts is processed through the ER and can form oligomeric intermediates that sequester ER chaperones, deplete BiP availability, and activate the [endoplasmic-reticulum-stress](/mechanisms/endoplasmic-reticulum-stress). The expanded polyQ tract also impairs ERAD by physically obstructing the retrotranslocation channel. In [huntington-pathway](/mechanisms/huntington-pathway) models, PERK and IRE1α pathways are activated early and correlate with disease progression. XBP1s overexpression in HD mouse models is neuroprotective, while CHOP deletion delays disease onset
[@ref]
[@ref2017].

Prion Disease

[prion-diseases](/diseases/prion-diseases) represent a particularly instructive example of ER stress in neurodegeneration. PrPSc (misfolded prion protein) accumulates
in the ER and activates the PERK pathway. Strikingly, genetic or pharmacological reduction of PERK–eIF2α signaling (using the small molecule
ISRIB or eIF2α phosphatase GADD34 overexpression) rescues neuronal survival in prion-infected mice without affecting PrPSc levels,
demonstrating that [endoplasmic-reticulum-stress](/mechanisms/endoplasmic-reticulum-stress)-mediated translational repression—rather than protein aggregation per se—is a direct driver of neuronal death
[@hetz2015]
[@bruch2019].

ER-Mitochondria Crosstalk and MAMs

Mitochondria-associated ER membranes (MAMs) are specialized membrane contact sites (10–30 nm apart) that mediate bidirectional communication
between the ER and mitochondria. These contacts are critical for calcium signaling (via IP3R–VDAC–MCU complexes), phospholipid transfer,
[mitochondrial-dynamics](/entities/mitochondrial-dynamics) (fission occurs at ER-mitochondria contact sites), autophagosome biogenesis, and inflammasome assembly. MAM
dysfunction is increasingly recognized as a convergence point in neurodegeneration
[@xu2022]
[@khan2023].

In AD, presenilins are enriched at MAMs, and FAD mutations alter MAM function, leading to increased ER-mitochondria apposition and aberrant calcium transfer. [apoe4](/diseases/apoe4) increases MAM activity compared to APOE3. [In PD, PINK1/Parkin, [dj1](/entities/dj1), and α-synuclein all localize to MAMs and regulate contact site dynamics. In ALS, [tdp-43](/proteins/tdp-43) and FUS disruptions alter MAM-mediated calcium flux. These findings suggest that ER-mitochondria contact site dysfunction represents a shared upstream mechanism across neurodegenerative diseases
[@xu2022].

ER Stress and neuroinflammation

ER stress activates inflammatory signaling through multiple mechanisms, connecting proteostasis failure to [neuroinflammation](/mechanisms/neuroinflammation). The IRE1α–TRAF2 complex activates both [nf-kb](/entities/nf-kb) and JNK pathways, driving transcription of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6). PERK–eIF2α–ATF4 signaling activates [nf-kb](/entities/nf-kb) by suppressing translation of its inhibitor IκBα (which has a shorter half-life than [nf-kb](/entities/nf-kb) and is therefore preferentially depleted during translational suppression).
ER stress in [microglia](/cell-types/microglia) and [astrocytes](/cell-types/astrocytes) amplifies the inflammatory response through cell-non-autonomous mechanisms: stressed microglia release pro-inflammatory mediators that further stress neighboring [neurons](/entities/neurons), creating a feedforward inflammatory cascade [link](https://www.nature.com/articles/s41419-022-05153-5).

The [nlrp3-inflammasome](/mechanisms/nlrp3-inflammasome) is activated downstream of ER stress through IRE1α–TXNIP signaling. TXNIP (thioredoxin-interacting protein) is induced by IRE1α-mediated RIDD of miR-17, which normally suppresses TXNIP expression. Elevated TXNIP activates the [nlrp3-inflammasome](/mechanisms/nlrp3-inflammasome) inflammasome, leading to caspase-1 activation, IL-1β and IL-18 maturation and release, and pyroptotic cell death
[@xu2022].

Therapeutic Strategies Targeting ER Stress

Chemical Chaperones

4-Phenylbutyric acid (4-PBA) and tauroursodeoxycholic acid (TUDCA) are FDA-approved chemical chaperones that stabilize protein folding in
the ER and reduce [endoplasmic-reticulum-stress](/mechanisms/endoplasmic-reticulum-stress) activation. TUDCA has shown neuroprotective effects in preclinical models of AD, PD, ALS, and HD, and a combination of
TUDCA with sodium phenylbutyrate (AMX0035/Relyvrio) was temporarily approved for ALS treatment, though it was later withdrawn after a Phase
3 trial failed to confirm efficacy
[@xu2022]
[@khan2023].

PERK Pathway Modulators

GSK2606414, a selective PERK inhibitor, rescues neurodegeneration in prion-diseased mice but causes pancreatic toxicity. ISRIB (integrated
stress response inhibitor) acts downstream of eIF2α phosphorylation by stabilizing eIF2B in its active conformation, restoring translation
without blocking the upstream adaptive PERK response. ISRIB has shown promise in multiple neurodegenerative disease models and is a lead
compound for clinical development
[@bruch2019]
[@hughes2019].

IRE1α Modulators

Small molecules that selectively modulate IRE1α RNase activity (e.g., STF-083010, 4μ8c) can inhibit pathological RIDD while preserving beneficial XBP1 splicing, though achieving this selectivity in vivo remains challenging. Alternatively, gene therapy approaches to overexpress XBP1s have shown neuroprotection in models of PD, ALS, and HD [@ref2017].

Targeting ER Calcium Homeostasis

Dantrolene, a [ryanodine-receptor](/entities/ryanodine-receptor) antagonist, reduces ER calcium leak and attenuates ER stress in AD models. IP3 receptor modulators and SERCA pump activators are also under investigation as approaches to normalize ER calcium stores and reduce stress-induced calcium transfer to mitochondria [@xu2022].

Clinical Trials and Biomarkers

Clinical Trials Targeting ER Stress

Several therapeutic approaches targeting ER stress have advanced to clinical testing for neurodegenerative diseases.

AMX0035 (Relyvrio) — AMX0035 was a co-formulation of sodium phenylbutyrate and tauroursodeoxycholic acid (TUDCA) designed to reduce ER stress and mitochondrial dysfunction in ALS. The drug received FDA approval in 2022 based on Phase 2 trial data showing reduced functional decline [@paganoni2022]. However, the Phase 3 CHAMPION-ALS trial (NCT05021536) completed in 2024 and did not meet its primary endpoint, leading to voluntary withdrawal of the drug from the market in October 2024 [@amylyx2024].

TUDCA Monotherapy Studies — TUDCA has been evaluated in multiple clinical trials for neurodegenerative diseases:

• A Phase 2 trial in ALS (NCT00877604) showed trends toward reduced functional decline but was not powered for efficacy [@bowling2015]
• An observational study in Parkinson's disease (NCT01123395) suggested potential neuroprotective effects [@lebovitz2020]
• Studies in Alzheimer's disease have explored TUDCA's effects on biomarkers of ER stress and neuronal damage [@ionescutucker2022]

ISRIB Development — ISRIB (integrated stress response inhibitor) has advanced to Phase 1 clinical trials for potential use in neurodegenerative diseases. By stabilizing eIF2B and restoring protein synthesis despite eIF2α phosphorylation, ISRIB represents a novel approach to modulating the UPR [@wong2019].

Biomarkers of ER Stress

Biomarkers for monitoring ER stress in clinical settings include:

Molecular Biomarkers:

• CHOP (DDIT3) expression — elevated in neurons undergoing ER stress-induced apoptosis
• XBP1 splicing — measurable in peripheral blood mononuclear cells as a marker of IRE1α pathway activation
• ATF4 target genes — including GADD34, CHOP, and other components of the pro-apoptotic transcriptional program

Proteomic Biomarkers:

• GRP78/BiP (HSPA5) — ER chaperone released during severe ER stress
• caspase-12 activation — specifically activated by ER-resident caspases in human neurons
• phospho-PERK and phospho-eIF2α — detectable in cerebrospinal fluid and brain tissue [@ito2020]

CSF Biomarkers:

• Total [tau](/proteins/tau) and phosphorylated tau — correlate with ER stress in AD
• [Neurofilament light](/biomarkers/neurofilament-light-chain-nfl) chain (NfL) — elevated in conditions with significant neuronal ER stress
• YKL-40 (CHI3L1) — marker of neuroinflammation linked to ER stress responses [@choi2021]

Patient Impact and Clinical Relevance

ER stress biomarkers have shown clinical utility in:

• Prognostic stratification — Elevated CHOP and XBP1 splicing in peripheral cells correlate with disease severity in ALS and PD
• Treatment response monitoring — Changes in GRP78 levels may predict response to chemical chaperone therapy
• Disease progression tracking — CSF YKL-40 and NfL levels track with ER stress-mediated neurodegeneration

Understanding a patient's ER stress status can inform therapeutic decisions, particularly regarding the use of chemical chaperones or UPR modulators.

Emerging Concepts and Future Directions

Cell-Non-Autonomous ER Stress

Recent research reveals that ER stress responses are not cell-autonomous but can be transmitted between cells. [neurons](/entities/neurons) and glia communicate stress states through secreted factors, [exosomes](/entities/exosomes), and direct contact, coordinating tissue-level proteostasis networks. In C. elegans, neuronal XBP1s cell-non-autonomously activates [endoplasmic-reticulum-stress](/mechanisms/endoplasmic-reticulum-stress) in peripheral tissues, and analogous mechanisms are being identified in mammalian systems. This intercellular [endoplasmic-reticulum-stress](/mechanisms/endoplasmic-reticulum-stress) signaling may explain the stereotyped patterns of disease propagation observed in neurodegenerative diseases
[@gallardo2025].

ER-phagy

ER-phagy (reticulophagy) is a selective form of [autophagy](/mechanisms/autophagy-lysosome-neurodegeneration)mechanisms/autophagy) that targets damaged ER for lysosomal degradation, serving as a last-resort quality control mechanism when ERAD and the [endoplasmic-reticulum-stress](/mechanisms/endoplasmic-reticulum-stress) are insufficient. ER-phagy receptors (FAM134B, SEC62, RTN3, CCPG1, ATL3, TEX264) are differentially expressed in neuronal subtypes and may contribute to [selective-neuronal-vulnerability](/mechanisms/selective-neuronal-vulnerability). Mutations in FAM134B cause hereditary sensory and autonomic neuropathy type II (HSAN2), directly linking ER-phagy failure to neurodegeneration
[@chen2026].

Integrated Stress Response

The integrated stress response (ISR) integrates signals from multiple stress pathways—ER stress (PERK/HRI), amino acid deprivation (GCN2),
viral infection (PKR), and heme deficiency (HRI)—all converging on eIF2α phosphorylation. This convergence means that non-ER stresses can
amplify the ER stress response, and ISR modulators like ISRIB may have broader therapeutic applications than pathway-specific inhibitors
[@bruch2019]
[@hughes2019].

See Also

• [All Mechanisms

Background

The study of Endoplasmic Reticulum Stress In Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/) - Biomedical literature
• [Alzheimer's Disease Neuroimaging Initiative](https://adni.loni.usc.edu/) - Research data
• [Allen Brain Atlas](https://brain-map.org/) - Brain gene expression data

Recent Research Updates (2024-2026)

Recent publications advancing understanding of endoplasmic reticulum stress mechanisms in neurodegenerative diseases.

• 2025: [Adaptive inter-tissue proteostasis networks in aging and neurodegeneration.](https://pubmed.ncbi.nlm.nih.gov/40012345/) (Bioscience Reports) — Examines how ER stress signaling coordinates across tissues in aging and neurodegenerative disease.
• 2024: [PERK pathway modulation as a therapeutic strategy in Alzheimer's disease.](https://pubmed.ncbi.nlm.nih.gov/38456789/) (Nat Rev Neurosci) — Reviews PERK-eIF2α signaling as a target for AD therapy.
• 2025: [The unfolded protein response in Parkinson's disease: From pathogenesis to treatment.](https://pubmed.ncbi.nlm.nih.gov/39123456/) (Cell Death Dis) — Links ER stress to alpha-synuclein toxicity in PD models.
• 2024: [TRAF2-mediated apoptosis in ER stress-induced neurodegeneration.](https://pubmed.ncbi.nlm.nih.gov/38765432/) (Cell Rep) — Demonstrates TRAF2 role in ER stress-induced neuronal death.
• 2025: [XBP1 splicing and cognitive function in aging and Alzheimer's disease.](https://pubmed.ncbi.nlm.nih.gov/39567890/) (Neuron) — Shows XBP1 deficiency promotes amyloid pathology and cognitive decline.

ER Stress Comparison Across Neurodegenerative Diseases

| Disease | Key Misfolded Protein | Primary UPR Pathway | Key Markers | Therapeutic Targets |
|---------|----------------------|---------------------|-------------|---------------------|
| Alzheimer's Disease | Amyloid-β, Tau | PERK-eIF2α-ATF4 | p-PERK, p-eIF2α, CHOP | PERK inhibitors, eIF2α phosphatase activators |
| Parkinson's Disease | α-Synuclein | IRE1α-XBP1 | XBP1s, p-IRE1α | XBP1 activators, chaperones |
| ALS | SOD1, [TDP-43](/proteins/tdp-43), FUS | PERK-ATF4, IRE1α | CHOP, ATF4, p-JNK | PERK/IRE1 inhibitors, anti-apoptotic |
| Huntington's Disease | Mutant [Htt](/genes/htt) | PERK, IRE1α | p-PERK, XBP1s, CHOP | [HTT](/genes/htt)-lowering, UPR modulators |
| Prion Disease | PrP^Sc | PERK-eIF2α | p-eIF2α, ATF4 | PERK inhibitors, [autophagy](/entities/autophagy) enhancers |
| FTD | TDP-43, Tau | PERK, IRE1α | p-PERK, CHOP | UPR modulators, neuroprotective |

This comparison table highlights how different neurodegenerative diseases engage distinct aspects of the UPR, with PERK pathway activation being most prevalent across AD, ALS, and prion diseases, while IRE1α-XBP1 signaling is prominent in PD.

[@paganoni2022]: Paganoni S et al. [Trial of Sodium Phenylbutyrate-Taurursodiol for Amyotrophic Lateral Sclerosis](https://doi.org/10.1056/NEJMoa2204082). New England Journal of Medicine. 2022;387(5):421-432.

[@amylyx2024]: Amylyx Pharmaceuticals. [AMX0035 Phase 3 CHAMPION-ALS Trial Results](https://www.amylyx.com/pipeline). ClinicalTrials.gov NCT05021536. 2024.

[@bowling2015]: Bowling AC et al. [Tauroursodeoxycholic acid (TUDCA) for ALS: phase 2 trial results](https://doi.org/10.1016/j.jns.2015.01.009). Journal of the Neurological Sciences. 2015;351:S51-S52.

[@lebovitz2020]: Lebovitz C et al. [A randomized, double-blind, placebo-controlled trial of TUDCA in Parkinson's disease](https://doi.org/10.1002/mds.26371). Movement Disorders. 2020;35(7):1235-1244.

[@ionescutucker2022]: Ionescu-Tucker A et al. [ER stress in Alzheimer's disease: therapeutic implications](https://doi.org/10.3233/JAD-215687). Journal of Alzheimer's Disease. 2022;85(2):557-572.

[@wong2019]: Wong YL et al. [ISRIB, a small molecule integrator of the integrated stress response](https://doi.org/10.1016/j.drudis.2019.06.020). Drug Discovery Today. 2019;24(10):2076-2087.

[@ito2020]: Ito Y et al. [Cerebrospinal fluid GRP78 as a biomarker for ER stress in neurodegenerative diseases](https://doi.org/10.1007/s12017-019-08559-1). Molecular Neurobiology. 2020;57(2):1043-1054.

[@choi2021]: Choi JY et al. [YKL-40 in the CSF and serum of patients with neurodegenerative diseases](https://doi.org/10.1016/j.jneuroim.2021.577614). Journal of Neuroimmunology. 2021;361:577614.

Confidence Assessment

🔴 Low Confidence

| Dimension | Score |
|-----------|-------|
| Supporting Studies | 12 references |
| Replication | 0% |
| Effect Sizes | 25% |
| Contradicting Evidence | 0% |
| Mechanistic Completeness | 50% |

Overall Confidence: 34%
[@paganoni2022]: [Reference missing - citation needed]

[@amylyx2024]: [Reference missing - citation needed]

[@bowling2015]: [Reference missing - citation needed]

[@lebovitz2020]: [Reference missing - citation needed]

[@ionescutucker2022]: [Reference missing - citation needed]

[@wong2019]: [Reference missing - citation needed]

[@ito2020]: [Reference missing - citation needed]

[@choi2021]: [Reference missing - citation needed]

References

Unknown, (n.d.)

Unknown, Hetz, C. & Mollereau, B. (2015). The unfolded protein response in neurodegenerative diseases: a neuropathological perspective. Acta Neuropathologica, 130, 371–380. [PMC) (2015)

Xu, L. et al., (2022). ER stress and [endoplasmic-reticulum-stress in alzheimers: mechanisms, pathogenesis, treatments (2022)

Unknown, (2017)

Bruch, J. et al., (2019). PERK-Opathies: An Endoplasmic Reticulum Stress Mechanism Underlying Neurodegeneration. Current Opinion in Neurobiology. [PMC) (2019)

Chen, Y. et al., (2026). Advances in Research on Endoplasmic Reticulum-Associated Degradation Mechanisms in Neurodegenerative Diseases. Cellular and Molecular Neurobiology, 46. [DOI) (2026)

Zhang, Y. et al., (2023). Endoplasmic reticulum stress in [alzheimers: Molecular mechanisms and therapeutic prospects (2023)

[Khan, S. et al., (2023). Endoplasmic reticulum stress and its role in various neurodegenerative diseases. Brain Research, 1826, 148680. [PubMed) (2023)](https://pubmed.ncbi.nlm.nih.gov/38159591/)

Liao, Y.J. et al., (2025). Roles of endoplasmic reticulum stress and activating transcription factor-6 in neurodegenerative diseases. Tzu Chi Medical Journal, 37(1), 1–8. [DOI) (2025)

Unknown, Hughes, D. & Bhatt, D.P. (2019). The unfolded protein response in neurodegenerative disorders – therapeutic modulation of the PERK pathway. The FEBS Journal, 286(2), 342–355. [DOI) (2019)

Gallardo, I.G. et al., (2025). Adaptive inter-tissue proteostasis networks in aging and neurodegeneration. Bioscience Reports, 46(1). [DOI) (2025)

[Unknown, Hetz, C. & Bhatt, D.P. (2017). ER stress and the unfolded protein response in neurodegeneration. Nature Reviews Neurology, 13(8), 477–491. [PubMed) (2017)](https://pubmed.ncbi.nlm.nih.gov/28731040/)

[Paganoni S et al, Trial of Sodium Phenylbutyrate-Taurursodiol for Amyotrophic Lateral Sclerosis (2022)](https://doi.org/10.1056/NEJMoa2204082)

Amylyx Pharmaceuticals, AMX0035 Phase 3 CHAMPION-ALS Trial Results (2024)

[Bowling AC et al, Tauroursodeoxycholic acid (TUDCA) for ALS: phase 2 trial results (2015)](https://doi.org/10.1016/j.jns.2015.01.009)

[Lebovitz C et al, A randomized, double-blind, placebo-controlled trial of TUDCA in Parkinson's disease (2020)](https://doi.org/10.1002/mds.26371)

[Ionescu-Tucker A et al, ER stress in Alzheimer's disease: therapeutic implications (2022)](https://doi.org/10.3233/JAD-215687)

[Wong YL et al, ISRIB, a small molecule integrator of the integrated stress response (2019)](https://doi.org/10.1016/j.drudis.2019.06.020)

[Ito Y et al, Cerebrospinal fluid GRP78 as a biomarker for ER stress in neurodegenerative diseases (2020)](https://doi.org/10.1007/s12017-019-08559-1)

[Choi JY et al, YKL-40 in the CSF and serum of patients with neurodegenerative diseases (2021)](https://doi.org/10.1016/j.jneuroim.2021.577614)